Profile of darunavir in the treatment of HIV-infected pediatric and adolescent patients

References

• GortmakerSHughesMCerviaJEffect of combination therapy including protease inhibtors on mortality among children and adolescents infected with HIV-1N Engl J Med20013451522152811794218
   PubMed Web of Science ®Google Scholar
• GonaPvan DykeRWilliamsPLIncidence of opportunistic and other infections in HIV-infected children in the HAART eraJAMA2006296292300016849662
   PubMed Web of Science ®Google Scholar
• MurphyDASarrMDurakoSJMoscickiABWilsonCMMuenzLRAdolescent Medicine HIV/AIDS Research NetworkBarriers to HAART adherence among human immunodeficiency virus-infected adolescentsArch Pediatr Adolesc Med200315724925512622674
   PubMed Web of Science ®Google Scholar
• MerzelCVandervanterNIrvineMAdherence to antiretroviral therapy among older children and adolescents with HIV: a qualitative study of psychosocial contextsAIDS Patient Care STDS20082297798719072104
   PubMed Web of Science ®Google Scholar
• KearnsGLAbdel-RahmanSMAlanderSWBloweyDLLeederJSKaufmannREDevelopmental pharmacology – drug disposition, action, and therapy in infants and childrenN Engl J Med20033491157116713679531
   PubMed Web of Science ®Google Scholar
• FletcherCVAntiviral drug-drug interaction considerations for HIV-infected childrenPediatr Infect Dis J20092842943019395949
   PubMed Web of Science ®Google Scholar
• MensonENWalkerASSharlandNCollaborative HIV Paediatric Study Steering CommitteeUnderdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997–2005: cohort studyBMJ20063321183118716709991
   PubMed Web of Science ®Google Scholar
• FlorenLCWizniaAHayashiSPediatric AIDS Clinical Trials Group Protocol 377 TeamNelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trial Group Protocol 377Pediatrics2003112e220e22712949316
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Therapy and Medical Management of HIV-infected ChildrenGuidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection: August 11, 2011Rockville, MDAIDSinfo201137 Available from: http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdfAccessed September 5, 2011
   Google Scholar
• ClotetBBellosNMolinaJMPOWER 1 and 2 study groupEfficacy and safety of darunavir-ritonavir at week 48 in treatment experienced patients with HIV-infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trialsLancet20073691169117817416261
   PubMed Web of Science ®Google Scholar
• OrtizRDejesusEKhanlouHEfficacy and safety of once daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1-infected patients at week 48AIDS2008221389139718614861
   PubMed Web of Science ®Google Scholar
• BlancheSBolognaRCahnPPharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment experienced children and adolescentsAIDS2009232005201319724191
   PubMed Web of Science ®Google Scholar
• RosenbergMAbadiJDobroszyckiJWizniaAProgress and challenges in antiretroviral therapy of HIV-infected childrenCurr Infect Dis Rep20068324331
   Google Scholar
• VolberdingPADeeksSGARV therapy and management of HIV infectionLancet2010376495220609987
   PubMed Web of Science ®Google Scholar
• McKeageKScottLJDarunavir in treatment-experienced pediatric patients with HIV-1 infectionPaediatr Drugs20101212313120218748
   PubMedGoogle Scholar
• NeelyMKovacsAManaging treatment-experienced pediatric and adolescent HIV patients: role of darunavirTher Clin Risk Manag2009559561519707276
   PubMedGoogle Scholar
• ValdezJDaniel BergerDMcMurchieMEfficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trialLancet2007370495817617272
   PubMed Web of Science ®Google Scholar
• ThuretIChaixMTamaletCRaltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virusAIDS2009232364236619823069
   PubMed Web of Science ®Google Scholar
• ArribasJRHorbanAGerstoftJThe MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/mlAIDS20102422323020010070
   PubMed Web of Science ®Google Scholar
• De MeyerSMJSpinosa-GuzmanSVangeneugdenTJde BéthuneMPMiralesGDEfficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavirJ Acquir Immune Defic Syndr20084917918218769351
   PubMed Web of Science ®Google Scholar
• MillsAMNelsonMJayaweeraDOnce-daily darunavir/ritonavir vs lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysisAIDS2009231679168819487905
   PubMed Web of Science ®Google Scholar
• DelaugerreCBuyckJFPeytavinGFactors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients the DARWEST studyJ Clin Virol20104724825220097121
   PubMed Web of Science ®Google Scholar
• ViolariABolognaRKimutarRARIEL: 24-week safety and efficacy of DRV/r in treatment-experienced 3- to <6-year-old patientsPoster 713, 18th CROI2011 Feb 27–Mar 2Boston, USA
   Google Scholar
• Prezista® Full Prescribing InformationTibotec TherapeuticsRaritan, NJ Revised122010
   Google Scholar
• KatlamaCHaubrichRLalezariJEfficacy and safety of etravirine in treatment-experienced, HIV-1 patients: Pooled week 48 analysis of two randomized, controlled trialsAIDS2009232289230019710593
   PubMed Web of Science ®Google Scholar
• WizniaASamsomPAcostaESafety and efficacy of raltegravir on pediatric HIV infectionPreliminary analysis from IMPAACT P1066Poster 874, 16th CROI2009 Feb 8–11Montreal, Canada
   Google Scholar
• LefebvreESchifferCAResilience to resistance of HIV-1 protease inhibitors: profile of darunavirAIDS Rev20081013114218820715
   PubMed Web of Science ®Google Scholar
• JohnsonVABrun-VézinetFClotetBUpdate of the drug resistance mutations in HIV-1: December 2010Top HIV Med20101815616321245516
   PubMedGoogle Scholar
• RheeSYGonzalesMJKantorRBettsBJRavelaJShaferRWHuman immunodeficiency virus reverse transcriptase and protease sequence databaseNucleic Acids Res20033129830312520007
   PubMed Web of Science ®Google Scholar
• De MeyerSDierynckILathouwersEPhenotypic and genotypic determinants of resistance to darunavir: analysis of data from treatment-experienced patients in POWER 1, 2, 3 and DUET-1 and 2Antiviral Ther200813Suppl 3A33
   Google Scholar
• De MeyerSDescampsDVan BaelenBConfirmation of the negative impact of protease mutations I47V, I54M, T74P, I84V and the positive impact of protease mutation V82A on virological response to darunavir/ritonavirAntiviral Ther200914Suppl 1A147
   Google Scholar
• BoydKWalkerSDunnDThe prevalence of darunavir associated mutations in PI-naive and PI-experienced HIV-1 infected children in the UKPoster 851, 17th CROI2010 Feb 16–19San Francisco, USA
   Google Scholar
• TremblayCLCombating HIV resistance – focus on darunavirTher Clin Risk Manag2008475976519209258
   PubMedGoogle Scholar
• PhillipsUKRosenbergMGDobroszyckiJPregnancy in women with perinatally acquired HIV-infection: outcomes and challengesAIDS Care20111117
   Google Scholar